Publications

Select keywords to filter the posts for matching content:

Keywords
Topics
  • Dermatologic Cooperative Oncology Group (DeCOG). Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.
    U. Hillen, U. Leiter, S. Haase, R. Kaufmann, J. Becker, R. Gutzmer, P. Terheyden, A. Krause-Bergmann, H. J. Schulze, J. Hassel, N. Lahner, U. Wollina, F. Ziller, J. Utikal, C. Hafner, J. Ulrich, H. G. Machens, C. Weishaupt, A. Hauschild, P. Mohr, C. Pföhler, J. Maurer, P. Wolff, C. Windemuth-Kieselbach, D. Schadendorf, E. Livingstone
    Study

    Year

    2018

    Keywords
    • squamous cell carcinoma
    • oncology
    • skin cancer
  • Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
    F. Griesinger, S. Radke, A. Lüers, B. Deschler-Baier, M. Kimmich, M. Sebastian, C. Schulz, W. Brugger, R. Wiewrodt, R. Pirker, M. Früh, O. Gautschi, J. Wolf
    Study

    Pneumologie 30408830

    Year

    2018

    Keywords
    • lung cancer
    • EGFR-TKI resistance
    • Osimertnip
    • oncology
  • Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study
    J. C. Becker, J. C. Hassel, C. Menzer, K. C. Kähler, T. K. Eigentler, F. E. Meier, C. Berking, R. Gutzmer, P. Mohr, F. Kiecker, M. Kaatz, C. Windemuth-Kieselbach, C. Lorenz-Schlüter, L. Zimmer, S.Ugurel, Dirk Schadendorf, and German Dermatooncology Group (DeCOG/ADO)
    Study

    ADMEC-O

    Year

    2018

    Keywords
    • Merkel cell carcinoma
    • skin cancer
    • ipilimumab
    • oncology
  • Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries
    G. Oskay-Özcelik, S. Alavi, R. Richter, M. Keller, R. Chekerov, S. C. Cecere, G. Cormio, F. Joly, J. E. Kurtz, A. du Bois, M. Maciejewski, M. Jedryka, I. Vergote, E. Van Nieuwenhuysen, A. Casado, C. Mendiola, P. Achimas-Cadariu, C. Vlad, D. Reimer, A. G. Zeimet, M. Friedlander, J. Sehouli
    Study

    EXPRESSION III

    Year

    2018

    Keywords
    • ovarian cancer
    • oncology
  • PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study
    R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran
    Study

    QoLiTime

    Year

    2018

    Keywords
    • cabazitaxel
    • prostate cancer
    • oncology
  • Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.
    T.Biester, B. Aschemeier, M. Fath, M. Frey, M. F. Scheerer, O. Kordonouri, T. Danne
    Study

    DAPA IIT179

    Year

    2017

    Keywords
    • dapagliflozin
    • type 1 diabetes
  • The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
    B. A. S. Jaeger BAS, J. Neugebauer, U. Andergassen, C. Melcher, F. Schochter, D. Mouarrawy, G. Ziemendorff, M. Clemens, V. E. Abel, G. Heinrich, K. Schueller, A. Schneeweiss, P. Fasching, M. W. Beckmann, C. Scholz, T. W. P. Friedl, K. Friese, K. Pantel, T. Fehm, W. Janni, B. Rack
    Study

    SUCCESS B

    Year

    2017

    Keywords
    • HER2
    • breast cancer
    • oncology
  • Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study
    R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran
    Study

    QoLiTime

    Year

    2017

    Keywords
    • cabazitaxel
    • mCRPC
    • QoL
    • oncology
  • PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives
    J. Sehouli, E. I. Braicu, R. Chekerov
    Study

    Year

    2016

    Keywords
    • PARP inhibitors
    • ovarian cancer
    • oncology
  • Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
    L. Zimmer, J. Vaubel, P. Mohr, A. Hauschild, J. Utikal, J. Simon, C. Garbe, R. Herbst, A. Enk, E. Kämpgen, E. Livingstone, L. Bluhm, R. Rompel, K. G. Griewank, M. Fluck, B. Schilling, D. Schadendorf
    Study

    Multibasket/DeCOG

    Year

    2015

    Keywords
    • uveal melanoma
    • ipilimumab
    • oncology
Follow:
Seite: 3/4